Visium Healthcare Partners said it will invest as much as $60.5 million in SomaLogic Inc. to help the Boulder biotech company advance development of such products as its diagnostic “Wellness Chip,” which can test for a variety of diseases.
“SomaLogic’s proprietary SOMAmer and SOMAscan technologies provide researchers and clinicians with a level of proteomic information that promises to revolutionize how diseases are diagnosed and treated,” Dr. Avi Amin, partner of Visium Healthcare Partners, said in a statement. “We believe that SomaLogic is an incredibly compelling emerging health care company and expect that this investment will help accelerate the realization of their ambitious vision and vast potential.”
Privately-held SomaLogic’s SOMAscan , which measure thousands of proteins to identify disease-indicating biomarkers, are used in clinics and research laboratories including the U.S. Food and Drug Administration’s National Center for Toxicological Research.
SomaLogic was founded in 2000 by Boulder biotech pioneer Larry Gold, who still serves as board chairman. Company officials were not immediately available for comment, but in a statement Gold said the debt and equity investment ”
provides us with the opportunity to even more quickly realize our ultimate goal of delivering much-needed new diagnostics tests to the clinic.”
Visium Healthcare Partners is a New York-based health care investment arm of Visium Asset Management..
Alicia Wallace: 303-954-1939, awallace@denverpost.com or @aliciawallace
